BioCentury
ARTICLE | Company News

UCLA, Bone Biologics deal

June 27, 2016 7:00 AM UTC

UCLA granted Bone Biologics an option to license exclusive, worldwide rights to use NEL-like protein 1 (NELL1) to treat osteoporosis. Bone Biologics is funding development of a NELL1-based product to...